Navigation Links
Data reaffirms test's ability to identify benign thyroid nodules

Aurora, CO (Oct. 23, 2013) The latest study co-led by a CU School of Medicine researcher has confirmed that a Gene Expression Classifier (GEC) test can drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment. These indeterminate nodules are being evaluated with a new molecular diagnostic test that measures the expression levels of 142 genes. This test is able to identify which initially indeterminate nodules are highly likely to be benign, and thus allows patients to avoid unnecessary diagnostic surgery.

This multi-site study co-led by Bryan R. Haugen, MD, professor of medicine and pathology at the University of Colorado School of Medicine provides the first long-term look at how these patients fared, and its findings reaffirm the performance of the Afirma Gene Expression Classifier (GEC). Haugen said "Each year, tens of thousands of patients with thyroid nodules have surgery to remove all or part of their thyroids. This is due to fine needle aspiration (FNA) cell test results that are indeterminate or inconclusive yet raise suspicions for thyroid cancer. Often times, most of these nodules prove to be benign. Our findings suggest that when the GEC identifies an otherwise indeterminate thyroid nodule as benign which it does about 50% of the time it is comparable in accuracy to a benign diagnosis by cytopathology, This fact and the degree to which physicians and patients in the study opted against surgery when the molecular test result was benign underscore the test's potential to drastically reduce the problem of unnecessary surgeries in thyroid nodule assessment."

Researchers analyzed all patients who had received Afirma GEC testing following indeterminate FNA biopsy results at five academic medical centers between 2010 and 2013. The GEC identified 174 of 339 (51%) indeterminate nodules as benign and, among these, 71 had documented clinical follow-up for an average of 9 months. Of these, only one nodule proved cancerous, demonstrating a very high negative predictive value (NPV) for the GEC. This finding is consistent with results from an earlier prospective, multicenter clinical study. Additionally, in the new study only 6% of patients with nodules identified as benign by the GEC test underwent surgery. This is a substantial reduction compared to traditional surgical rates for patients with cytologically indeterminate thyroid nodules.

Thyroid nodules are common, but only approximately 5-15% prove malignant. Most nodules are evaluated using FNA, with approximately 525,000 thyroid nodule FNAs performed in the U.S. in 2011 to rule out cancer. In most cases, the results are benign, yet in approximately 15-30% of cases the results are indeterminate not clearly benign or malignant. Because of the risk of thyroid cancer, most of these patients have historically been recommended for surgery to remove all or part of the thyroid to obtain a final diagnosis. However, such indeterminate nodules prove ultimately benign in 70-80% of cases. For these patients, the surgery was not needed and they were unnecessarily exposed to the cost, risk and morbidity of this intervention. Additionally, most patients subsequently require lifelong thyroid hormone therapy.

The study is published online in the Journal of Clinical Endocrinology & Metabolism and its findings were presented recently at the 83rd Annual Meeting of the American Thyroid Association, held in Puerto Rico.

The long-term findings built on the previous study which demonstrates the Afirma Gene Expression Classifier's accuracy was published in the New England Journal of Medicine.


Contact: Jackie Brinkman
University of Colorado Denver

Related medicine news :

1. ASTRO Chairman Michael Steinberg, M.D., FASTRO, reaffirms Societys commitment to ending self-referral
2. Passages Malibu Reaffirms Its Unshakable Commitment to Total Client Privacy
3. Pozzuolo Rodden, P.C., Philadelphia Business Planning Attorneys, Announce the Release of "IRS Reaffirms Its Commitment To Expand The Audits Of High Net Worth Individuals"
4. Tests in mice identify compound that may keep survivors of brain aneurysms from succumbing to stroke
5. Intact America Protests Good Samaritan’s Experimentation On Healthy Baby Boys
6. 2 tests in combination can provide better asthma diagnosis
7. Best Proxy Site for Video Streaming Goes to idcloak Following Speed Tests
8. PRISM Showcase Premiere on FX Network, Exclusive Content and Contests on
9. Breath tests could be used to diagnose lung cancer
10. Rapid diagnostic tests decrease waiting time for drug-resistant TB patients
11. Cellucor Kicks Off the P6 Blitz with Contests and Giveaways All September Long
Post Your Comments:
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also known ... people who find their cholesterol levels and weight are creeping up are more likely ... don’t have any of the other symptoms. , Thyroid hormone plays a major role ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis ... Care Plan software creates an agreement between the practice owner and the patient ... scheduling, monitoring, notification, and projections. Click here to learn more. ...
(Date:11/24/2015)... ... , ... Charitable giving is at its peak during the holidays. In ... of the year totalling over $358 billion in 2014. With more than 1.5 ... those individuals who want to “give back” during the holidays. , “With so many ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
(Date:11/24/2015)... Va. , Nov. 24, 2015  DILON Diagnostics ... have signed an agreement for DILON to distribute GE,s ... across the globe. The signing of this distribution agreement will ... NM750b Molecular Breast Imaging system and is considered an ... provide better healthcare solutions for clinicians and their patients. ...
Breaking Medicine Technology: